The Portuguese Association of Bioindustry Companies (P-BIO) launches the strategic plan Portugal Bio-Health 2030, which calls for greater investment in the sectors of Life Sciences and Biotechnology as a bet for an economy based on knowledge and knowledge. production of high added value products.
The strategic plan prepared by P-BIO has been presented, in recent months, to several Ministries, in a joint work to enrich the debate on the topic. The program already has more than 120 subscribers from different institutions, including members of the National Pharmacy Association (ANF), Portuguese Association of Medical Device Companies (APORMED), Portuguese Association of Hospital Administrators (APAH), Champalimaud Foundation, i3S – Institute for Research and Innovation in Health, Institute of Molecular Medicine (IMM), Institute of Pathology and Molecular Immunology of the University of Porto (IPATIMUP), Pfizer, Bial, Hovione or Sonae.
The Bio-Health 2030 plan aims to position Portugal as a center for Research and Development in Biotechnology and Life Sciences – turning Portugal into an R&D Hub – and a strategic pillar of production capacity in the European Union (EU), making our country the Europe Factory for Health.
Simão Soares, President of P-BIO, says: “The pandemic has confirmed that it is essential to invest today to ensure the health of the future. We have therefore prepared this strategic plan, which focuses on biotechnology, which we believe may be one of the important axes for recovering the economy, taking advantage of national capabilities in this area of knowledge and in alignment with the Recovery Plan and the framework multiannual financial plan for 2021-2027, which was recently approved by the European Council”.
The following proposals are part of the measures taken by Portugal Bio-Saúde 2030: Capacity building of the EU’s industrial fabric; Constitution of a strategic reserve of productive capacity for the EU in health; Promotion of highly qualified employment; Promotion of technology transfer with the financing of Venture Capital Funds specialized in Life Sciences; Promotion of research and clinical development in Portugal; Attraction of R&D centers in Health to Portugal.
The use of Life Sciences is essential for combating Covid-19 and occurs at various times, such as the identification of the virus and the diagnosis of patients, through laboratory tests of PCR; use of serological tests, which identify the incidence of infection and use antibodies (products of biotechnology); treatment of patients, with drugs or ventilators that belong to the areas of Life Sciences, Pharmaceuticals, Biopharmaceuticals and Medtech; in addition to the much desired vaccine, with development based on biotechnology.